21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). (September 2015) - Rosenberg, J.; Petrylak, D.; Abidoye, O.; Van der Heijden, M.S.; Hofman-Censits, J.; Necchi, A.; O'Donnell, P.H.; Balmanoukian, A.; Loriot, Y.; Retz, M.; Perez-Gracia, J.L.; Dawson, N.A.; et al.